Wladimir Hogenhuis Buys 4,259 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis bought 4,259 shares of Rezolute stock in a transaction on Tuesday, September 24th. The stock was acquired at an average price of $4.70 per share, for a total transaction of $20,017.30. Following the transaction, the director now directly owns 41,767 shares of the company’s stock, valued at $196,304.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rezolute Trading Up 5.5 %

RZLT stock opened at $4.95 on Thursday. The business’s fifty day moving average price is $4.62 and its 200 day moving average price is $3.78. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10. The company has a market capitalization of $274.08 million, a PE ratio of -4.34 and a beta of 1.18.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Research analysts predict that Rezolute, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. BTIG Research lifted their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Guggenheim began coverage on Rezolute in a research report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price on the stock. Maxim Group boosted their price objective on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $11.57.

Institutional Investors Weigh In On Rezolute

Several large investors have recently bought and sold shares of RZLT. Virtu Financial LLC purchased a new stake in Rezolute during the 1st quarter worth about $37,000. Jeppson Wealth Management LLC purchased a new stake in Rezolute during the 2nd quarter worth about $45,000. XTX Topco Ltd increased its holdings in Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the period. Acadian Asset Management LLC purchased a new stake in Rezolute during the 1st quarter worth about $229,000. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after acquiring an additional 42,597 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.